Provided is a method of screening a customized growth factor combination for cell culture, the method including: adding at least one growth factor and cells isolated from a subject to a culture medium; culturing the cells; and measuring cell proliferative activity of the cells. According to the method of screening cell-customized cell culture conditions according to one aspect, it is possible to efficiently select the optimal conditions for cell culture.

The present invention relates to a novel use of an antibody biding specifically to the N-terminus of lysyl-tRNA synthetase and, more particularly, to a pharmaceutical composition comprising an antibody biding specifically to an epitope including the sequence of SEQ ID NO: 117 in the N-terminal domain of lysyl-tRNA synthetase (KRS) or a functional fragment thereof as an effective ingredient for preventing and treating an immune cell migration-related disease. A KRS N-terminus-specific antibody provided by the present invention can regulate the migration of immune cells, thereby exhibiting very remarkable effects in the prevention, alleviation, and treatment of immune cell migration-related diseases.

A method of examining for cancer in a non-primate mammal such as a pet animal may include, for example, a method of examining or diagnosing for cancer in a non-primate mammal, including evaluating taxic behavior of nematodes toward a urine sample from a subject mammal.

This invention relates to a method for separating blood cells comprising the steps of: (a) lysing red blood cells of a blood sample and diluting said sample; (b) providing a microfluidic device comprising a spiral-shaped flow channel having at least a first end and a second end, wherein said flow channel has two inlet ports at or near said first end and at least two outlet ports at or near said second end, wherein one of the two inlet ports is located at the inner wall of the spiral-shaped flow channel and the other inlet port is located at the outer wall of the spiral-shaped flow channel and at least one of the outlet ports is connected to a container allowing the storage of blood cells; (c) introducing the sample of step (a) into the inlet port located at the outer wall of the spiral-shaped flow channel and introducing a sheath fluid into the inlet port located at the inner wall of the spiral-shaped flow channel; (d) driving said sample and the sheath fluid through the spiral-shaped flow channel; and (e) recovering the blood cell in the at least one container connected to the at least one outlet port. The present invention also relates to coupling above described method of purifying neutrophils in the native state with a method for diagnosing diabetes or an inflammatory disease in a subject, which involves further investigation of neutrophils by determining their rolling speed, the neutrophil circularity (NC) index and/or the expression of markers, such as intracellular reactive oxygen species (ROS), CD1 1 b or PSGL-1.

Disclosed herein is method and system for determining quality of semen sample. Trajectories of objects, identified in each of plurality of image frames of semen sample, are generated by tracking movement of the objects across image frames, and compensating a drift velocity of the semen sample. Further, generated trajectories are classified into sperm and non-sperm trajectories. Finally, total concentration estimate and total motility estimate of the semen sample are computed to generate a semen quality index, which indicates quality of the semen sample. In an embodiment, the method of present disclosure uses a multi-level Convolutional Neural Network (CNN) analysis technique for effectively classifying the object trajectories into sperm and non-sperm objects. Also, since the present method includes estimating and compensating drift velocity in the semen sample, it enhances overall accuracy of motility estimation and semen quality analysis.

An object of the present invention is to provide a novel evaluation system that is particularly useful in researches on the onset mechanism and pathologic conditions of a central nervous system disease, development of a therapeutic method, or the like. The efficacy of a test substance is evaluated using a movement pattern defined by variations in movement of individual cells constituting a cell population as an index.

The present invention provides a method for predicting a therapeutic effect and/or monitoring recurrence in a cancer patient. Disclosed is a method for detecting a therapeutic effect of cancer treatment in a cancer patient, comprising: measuring nematode tactic behavior to each of pre-treatment urine and in-treatment or post-treatment urine from the cancer patient; and comparing a result of measuring the tactic behavior to the pre-treatment urine and a result of measuring the tactic behavior to the in-treatment or post-treatment urine, wherein when attraction is weakened or avoidance is strengthened after the treatment, it is determined that the therapeutic effect is detected.

A cell analysis system according to the present disclosure includes a motion information extracting unit and a motion characteristics calculating unit. The motion information extracting unit extracts motion information arising from a movement of ions or molecules across a cell membrane, out of a cell image obtained from imaging a cell in time series. The motion characteristics calculating unit calculates motion characteristics of the motion information.

The present disclosure relates to methods for performing assays for active migration and cytotoxicity of a therapeutic agent towards tumor cells, e.g., immune cell and/or drug homing, migration, and tumor cytotoxicity. The methods are performed in labware that provide opportunities for a therapeutic agent, such as an immune cell or a drug, to migrate toward tumor cells, including tumor cells growing in a 3D spheroid conformation. The methods allow for, among other uses, the investigation of the effects of a therapeutic agent, such as immune cells or a drug, on tumor cells, and enable the investigation of homing, tumor cytotoxicity, and tumor immune evasion in a single, easy-to-use, high throughput system for more in vivo-like testing.

The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.